Viridian Therapeutics, Inc. VRDN Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s accrued liabilities, current?
- Viridian Therapeutics, Inc. (VRDN) reported accrued liabilities, current of $38.49M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s accrued liabilities, current changed year-over-year?
- Viridian Therapeutics, Inc.'s accrued liabilities, current increased by 30.2% year-over-year, from $29.55M to $38.49M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s accrued liabilities, current has grown at a 44.9% compound annual growth rate (CAGR), from $9.7M to $62.01M.